| Rheumatoid arthritis |
2.46 |
0.00e+0 |
78/93 (83.87%) |
CXCL2;CXCL8;CXCL5;...
|
| Viral protein interaction with cytokine and cytokine re... |
2.42 |
0.00e+0 |
84/100 (84%) |
CXCL2;CXCL8;CXCL5;...
|
| NF-kappa B signaling pathway |
2.39 |
0.00e+0 |
90/104 (86.54%) |
CD40;CXCL2;CXCL8;...
|
| TNF signaling pathway |
2.36 |
0.00e+0 |
103/112 (91.96%) |
CXCL2;CXCL5;CXCL1;...
|
| Chemokine signaling pathway |
2.22 |
0.00e+0 |
163/192 (84.9%) |
CXCL2;CXCL8;CXCL5;...
|
| Th17 cell differentiation |
2.18 |
0.00e+0 |
95/107 (88.79%) |
HLA-DRB1;STAT3;HLA-DRA;...
|
| Amoebiasis |
2.17 |
0.00e+0 |
99/102 (97.06%) |
CXCL2;CXCL8;CXCL1;...
|
| Intestinal immune network for IgA production |
2.03 |
3.43e-3 |
38/48 (79.17%) |
CD40;HLA-DRB1;HLA-DRA;...
|
| Th1 and Th2 cell differentiation |
2.03 |
3.05e-3 |
80/92 (86.96%) |
HLA-DRB1;HLA-DRA;HLA-DPB1;...
|
| AGE-RAGE signaling pathway in diabetic complications |
2.03 |
2.74e-3 |
97/100 (97%) |
CXCL8;STAT3;IL6;...
|
| Epithelial cell signaling in Helicobacter pylori infect... |
2.02 |
3.74e-3 |
62/70 (88.57%) |
CXCL2;CXCL8;CXCL1;...
|
| Lipid and atherosclerosis |
2.02 |
3.43e-3 |
190/215 (88.37%) |
CD40;CXCL2;CXCL8;...
|
| Kaposi sarcoma-associated herpesvirus infection |
2.00 |
3.16e-3 |
172/193 (89.12%) |
CXCL2;CXCL8;CXCL1;...
|
| Acute myeloid leukemia |
1.98 |
3.92e-3 |
66/67 (98.51%) |
STAT3;LEF1;PIK3CD;...
|
| IL-17 signaling pathway |
1.96 |
4.57e-3 |
84/94 (89.36%) |
CXCL2;CXCL8;CXCL5;...
|
| Longevity regulating pathway |
1.94 |
4.28e-3 |
90/151 (59.6%) |
CREB1;SOD2;BAX;...
|
| NOD-like receptor signaling pathway |
1.94 |
4.03e-3 |
145/181 (80.11%) |
CXCL2;CXCL8;CXCL1;...
|
| Cytokine-cytokine receptor interaction |
1.90 |
4.57e-3 |
246/295 (83.39%) |
CD40;CXCL2;CXCL8;...
|
| Inflammatory bowel disease |
1.89 |
5.77e-3 |
58/65 (89.23%) |
HLA-DRB1;STAT3;HLA-DRA;...
|
| Asthma |
1.88 |
5.48e-3 |
25/31 (80.65%) |
CD40;HLA-DRB1;HLA-DRA;...
|
| Leishmaniasis |
1.87 |
5.87e-3 |
67/77 (87.01%) |
HLA-DRB1;HLA-DRA;CYBA;...
|
| Salmonella infection |
1.85 |
6.85e-3 |
198/249 (79.52%) |
CXCL8;RHOB;GAPDH;...
|
| C-type lectin receptor signaling pathway |
1.84 |
7.15e-3 |
93/104 (89.42%) |
MAPKAPK2;IL6;BCL3;...
|
| Toxoplasmosis |
1.82 |
9.14e-3 |
103/112 (91.96%) |
CD40;HLA-DRB1;STAT3;...
|
| Legionellosis |
1.81 |
9.32e-3 |
51/57 (89.47%) |
CXCL2;CXCL8;CXCL1;...
|
| Propanoate metabolism |
1.80 |
8.96e-3 |
30/34 (88.24%) |
ABAT;LDHB;ALDH6A1;...
|
| Systemic lupus erythematosus |
1.79 |
1.02e-2 |
45/135 (33.33%) |
CD40;HLA-DRB1;HLA-DRA;...
|
| Butanoate metabolism |
1.78 |
1.08e-2 |
23/28 (82.14%) |
ABAT;BDH2;GAD1;...
|
| African trypanosomiasis |
1.77 |
1.04e-2 |
32/37 (86.49%) |
IL6;F2RL1;ICAM1;...
|
| Primary immunodeficiency |
1.77 |
1.10e-2 |
33/38 (86.84%) |
CD40;BLNK;IL2RG;...
|
